Neuphoria Therapeutics Inc. Operating Lease Cost
Neuphoria Therapeutics Inc. (NEUP) reported Operating Lease Cost of $65.28 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-09-18
- Neuphoria Therapeutics Inc. operating lease, cost for the quarter ending 2026-06-30 was $0.00.
- Neuphoria Therapeutics Inc. operating lease, cost for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Neuphoria Therapeutics Inc. operating lease, cost for the quarter ending 2025-12-31 was $65.28K, a 104.67% increase year-over-year.
- Neuphoria Therapeutics Inc. operating lease, cost for the quarter ending 2025-09-30 was $32.63K, a 7.22% increase year-over-year.
- Neuphoria Therapeutics Inc. operating lease, cost for fiscal 2026 was $65.28K, a 30.46% decline from fiscal 2025.
- Neuphoria Therapeutics Inc. operating lease, cost for fiscal 2025 was $93.88K, a 27.46% decline from fiscal 2024.
- Neuphoria Therapeutics Inc. operating lease, cost for fiscal 2024 was $129.41K, a 4.90% decline from fiscal 2023.
- Neuphoria Therapeutics Inc. operating lease, cost for fiscal 2023 was $136.08K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | $0.00 derived: sum of 2 quarters · filed 2026-09-18 | $65.28K derived: sum of 3 quarters · filed 2026-09-18 | $65.28K 10-K · filed 2026-09-18 | ||
| 2026-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | $65.28K derived: sum of 2 quarters · filed 2026-05-15 | $65.28K 10-Q · filed 2026-05-15 | $97.92K derived: sum of 4 quarters · filed 2026-09-18 | ||
| 2025-12-31 | $65.28K 10-Q · filed 2026-02-17 | $65.28K 10-Q · filed 2026-02-17 | $97.92K derived: sum of 3 quarters · filed 2026-09-18 | $129.71K derived: sum of 4 quarters · filed 2026-09-18 | ||
| 2025-09-30 | $32.63K 10-Q · filed 2025-11-14 | $32.63K derived: sum of 2 quarters · filed 2026-09-18 | $64.42K derived: sum of 3 quarters · filed 2026-09-18 | $96.32K derived: sum of 4 quarters · filed 2026-09-18 | ||
| 2025-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | $31.79K derived: sum of 2 quarters · filed 2026-09-18 | $63.69K derived: sum of 3 quarters · filed 2026-09-18 | $93.88K 10-K · filed 2026-09-18 | $96.76K 10-K · filed 2025-09-29 | |
| 2025-03-31 | $31.79K 10-Q · filed 2026-05-15 | $63.69K derived: sum of 2 quarters · filed 2026-05-15 | $93.88K 10-Q · filed 2026-05-15 | $126.77K derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2024-12-31 | $31.90K 10-Q · filed 2026-02-17 | $29.70K 10-Q · filed 2025-02-14 | $62.09K 10-Q · filed 2026-02-17 | $94.98K derived: sum of 3 quarters · filed 2026-02-17 | $127.14K derived: sum of 4 quarters · filed 2026-02-17 | |
| 2024-09-30 | $30.43K 10-Q · filed 2025-11-14 | $63.08K derived: sum of 2 quarters · filed 2025-11-14 | $95.24K derived: sum of 3 quarters · filed 2025-11-14 | $127.14K derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $32.65K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $64.81K derived: sum of 2 quarters · filed 2025-09-29 | $96.70K derived: sum of 3 quarters · filed 2025-09-29 | $129.41K 10-K · filed 2025-09-29 | ||
| 2024-03-31 | $32.16K 10-Q · filed 2025-05-20 | $64.06K derived: sum of 2 quarters · filed 2025-05-20 | $96.76K 10-Q · filed 2025-05-20 | |||
| 2023-12-31 | $31.90K 10-Q · filed 2025-02-14 | $64.60K 10-Q · filed 2025-02-14 | ||||
| 2023-09-30 | $29.72K 10-Q · filed 2024-11-14 | |||||
| 2023-06-30 | $136.08K 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |